Biopsy (NCT06423326)

Name: Biopsy trial for Borderline Resectable Pancreatic Ductal Adenocarcinoma (NCT06423326)
Uploaded: 2026-10-31T21:29:33.831Z
Duration: 1 min 23 s
Description: Biopsy trial for Borderline Resectable Pancreatic Ductal Adenocarcinoma (NCT06423326). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06423326.

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer: a one-minute explainerNCT064233261 min

Biopsy trial for Borderline Resectable Pancreatic Ductal Adenocarcinoma (NCT06423326). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for people over eighteen with pancreatic ductal adenocarcinoma that is removable or borderline removable, without distant spread. Participants must be active enough for the planned treatment.

The idea: give gemcitabine, cisplatin and nab-paclitaxel infusions every two weeks for up to four four-week cycles before surgery. These chemotherapy drugs interfere with DNA production, cancer-cell growth or cell division. Surgery follows if the cancer stays stable or responds. Biopsies, blood tests and scans assess treatment effects.

This phase 2 study plans 36 patients. Georgetown University sponsors one recruiting Atlanta site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.